Renalytix AI PLC Partnership with CDPHP on KidneyIntelX (1517Q)
October 17 2019 - 2:00AM
UK Regulatory
TIDMRENX
RNS Number : 1517Q
Renalytix AI PLC
17 October 2019
This announcement contained inside information
Renalytix AI plc
("RenalytixAI" or the "Company")
RenalytixAI Partners with Capital District Physicians' Health
Plan, Inc. on KidneyIntelX(TM)
Effective October 16, KidneyIntelX will be covered for
reimbursement for qualified members
Renalytix AI plc (AIM: RENX), a developer of artificial
intelligence-enabled clinical diagnostics for kidney disease,
announces that Capital District Physicians' Health Plan, Inc.
(CDPHP(R) ), a physician led health insurance provider, has adopted
coverage determination policies that will provide KidneyIntelX(TM)
for qualified CDPHP members who have Type 2 diabetes and chronic
kidney disease (diabetic kidney disease or "DKD"). In the United
States, approximately 12 million people currently have diabetic
kidney disease(1) . Qualified CDPHP members are eligible for
KidneyIntelX(TM) testing and score reporting for the risk of rapid
progression of kidney disease.
A coverage determination policy is a determination of whether
and under what circumstances a payor will pay for an item or
service. Insurance coverage is typically limited to items or
services that are considered by the payor as 'reasonable and
necessary' for the diagnosis or treatment of an illness or injury.
KidneyIntelX(TM) is designed to improve risk stratification and
clinical management of patients with DKD in an effort to improve
patient outcomes and health care system economics. KidneyIntelX(TM)
uses machine-learning algorithms to assess a combination of
predictive blood-based biomarkers and features from a patient's
electronic health record. The list price for KidneyIntelX(TM) is
$970 per reportable result.
John D. Bennett, MD, President and CEO of CDPHP said: "At CDPHP,
we have been on a mission to support our members with diabetes to
the best of our ability, offering programming and services to meet
their lifestyle choices and needs. Coverage of KidneyIntelX(TM) for
qualified members is a proactive step toward identifying and
treating fast-progressing kidney disease."
James McCullough, Chief Executive Officer of Renalytix AI plc
said: "This CDPHP coverage determination is an important milestone
for opening market access to the predictive value and data
assessment capacity of KidneyIntelX in this critical medical
indication. CDPHP is a progressive thinking physician led payor
group that is offering advanced technology solutions to help
patients experiencing rapid kidney function decline to slow or
prevent the devastating effects of end-stage renal disease and
dialysis."
One of the greatest drivers of health care cost today is
patients whose kidney disease is not diagnosed in time and face
kidney failure and unplanned transition to dialysis. Each year
kidney disease kills more people than breast and prostate cancer(2)
.
In a recent study published April 1 2019(3) , DKD patients who
scored high-risk by KidneyIntelX(TM) were 10 times more likely to
experience kidney failure than those who scored low-risk.For
patients experiencing rapid progression of kidney disease and
therefore most likely to advance toward end-stage renal disease and
dialysis, there are several clinical management strategies and
proven therapeutic options to slow the rate of disease progression
and/or halt its progress.
Notably in the same study, greater than 95% of patients with a
low KidneyIntelX(TM) score did not experience any progression of
their kidney disease over the next 5 years. As a result, even
though these patients have known diabetic kidney disease, they are
unlikely to progress with their disease further and can remain at a
primary care physician level for monitoring.
The person responsible for arranging the release of this
announcement on behalf of the Company is
James McCullough, CEO.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker) Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About Kidney Disease
Kidney disease is now recognised as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control estimates there that 15% of United States adults or 37
million people currently have kidney disease. It is reported that 9
out of 10 adults with chronic kidney disease do not know they have
it and 1 out of 2 people with very low kidney function who are not
on dialysis do not know they have CKD(4) . Kidney disease is
referred to as a "silent killer" because it often has no symptoms
and can go undetected until a very advanced stage. Each year kidney
disease kills more people than breast and prostate cancer. Every
day 13 patients die in the United States while waiting for a kidney
transplant.
About CDPHP(R)
Established in 1984, CDPHP is a physician-founded,
member-focused and community-based not-for-profit health plan that
offers high-quality affordable health insurance plans to members in
26 counties throughout New York. For more information visit
www.cdphp.com. CDPHP is also on Facebook, Twitter, LinkedIn, and
Instagram.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical in vitro diagnostic solutions for kidney disease, one of
the most common and costly chronic medical conditions globally. The
Company's products are being designed to make significant
improvements in kidney disease diagnosis, transplant management,
clinical care, patient stratification for drug clinical trials, and
drug target discovery. For more information, visit
renalytixai.com
Notes
1
https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease
2 https://www.ncbi.nlm.nih.gov/pubmed/30738630
3 https://www.biorxiv.org/content/10.1101/587774v1
4
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFSIIVLRLIA
(END) Dow Jones Newswires
October 17, 2019 02:00 ET (06:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024